Covid-19 roundup: CanSino’s inhaled vaccine gets thumbs-up from Chinese regulators; Sinovac gets go-ahead for booster trial in Chile

Tyler Patchen

News Reporter

While the world has been focused on injectable booster shots to address the Omicron variant, one company focused on a different approach has seen its product take a major step forward.

Chinese biotech CanSino Biologics has received approval from the National Medical Products Administration of China for its inhaled Covid-19 vaccine, dubbed Convidecia Air, to be used as a booster.

The company said that its booster uses an adenovirus vector platform and it touted the non-invasive nature of the vaccine, as compared to injectable jabs already on the market. The booster dose uses a nebulizer to change liquid into an aerosol so it can be inhaled via the mouth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: CanSino’s inhaled vaccine gets thumbs-up from Chinese regulators; Sinovac gets go-ahead for booster trial in Chile

Tyler Patchen

News Reporter

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Covid-19 roundup: CanSi­no’s in­haled vac­cine gets thumbs-up from Chi­nese reg­u­la­tors; Sino­vac gets go-ahead for boost­er tri­al in Chile

Tyler Patchen

News Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Covid-19 roundup: CanSino’s inhaled vaccine gets thumbs-up from Chinese regulators; Sinovac gets go-ahead for booster trial in Chile

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir